Sana Biotechnology (SANA) Stock Price, News & Analysis

Company Overview

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

Key Stats

• Today's Range: $2.98 to $3.15
• 50-Day Range: $1.60 to $4.30
• 52-Week Range: $1.52 to $12.00
• Volume: 2.23 million shs
• Average Volume: 3.22 million shs
• Market Capitalization: $672.04 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.25
• Consensus Rating: Moderate Buy

Sana Biotechnology Stock Analysis - MarketRank™

Sana Biotechnology scored higher than 61% of companies evaluated by MarketBeat, and ranked 397th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Sana Biotechnology has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Sana Biotechnology has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Sana Biotechnology are expected to grow in the coming year, from ($1.16) to ($0.84) per share.

Price to Book Value per Share Ratio

Sana Biotechnology has a P/B Ratio of 2.06. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

36.75% of the float of Sana Biotechnology has been sold short.

Short Interest Ratio / Days to Cover

Sana Biotechnology has a short interest ratio ("days to cover") of 6.8.

Change versus previous month

Short interest in Sana Biotechnology has recently decreased by 10.32%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Sana Biotechnology does not currently pay a dividend.

Dividend Growth

Sana Biotechnology does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

36.75% of the float of Sana Biotechnology has been sold short.

Short Interest Ratio / Days to Cover

Sana Biotechnology has a short interest ratio ("days to cover") of 6.8.

Change versus previous month

Short interest in Sana Biotechnology has recently decreased by 10.32%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.5 / 5
• News Sentiment: N/A

News Sentiment

Sana Biotechnology has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Sana Biotechnology this week, compared to 3 articles on an average week.

Search Interest

Only 8 people have searched for SANA on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.

MarketBeat Follows

Only 14 people have added Sana Biotechnology to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Sana Biotechnology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,888,019.00 in company stock.

Percentage Held by Insiders

31.10% of the stock of Sana Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

88.23% of the stock of Sana Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SANA Stock Analysis - Frequently Asked Questions

How have SANA shares performed this year?

Sana Biotechnology's stock was trading at $1.63 on January 1st, 2025. Since then, SANA shares have increased by 84.7% and is now trading at $3.01.
View the best growth stocks for 2025 here.

How were Sana Biotechnology's earnings last quarter?

Sana Biotechnology, Inc. (NASDAQ:SANA) released its earnings results on Friday, November, 8th. The company reported ($0.25) EPS for the quarter, topping analysts' consensus estimates of ($0.26) by $0.01.

When did Sana Biotechnology IPO?

Sana Biotechnology (SANA) raised $322 million in an initial public offering on Thursday, February 4th 2021. The company issued 15,000,000 shares at a price of $20.00-$23.00 per share. Morgan Stanley, Goldman Sachs, J.P. Morgan and BofA Securities served as the underwriters for the IPO.

Who are Sana Biotechnology's major shareholders?

Sana Biotechnology's top institutional shareholders include Vanguard Group Inc. (4.81%), Baillie Gifford & Co. (4.58%), Geode Capital Management LLC (1.43%) and Price T Rowe Associates Inc. MD (1.39%). Insiders that own company stock include Robert Nelsen, Fmr Llc, Richard Mulligan, Ventures Fund V Gener Flagship and Joshua H Bilenker.
View institutional ownership trends.

How do I buy shares of Sana Biotechnology?

Shares of SANA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Sana Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Sana Biotechnology investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Walmart (WMT).

Company Calendar

• Last Earnings: 11/08/2024
• Today: 2/21/2025
• Next Earnings (Estimated): 5/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SANA
• CUSIP: N/A
• CIK: 1770121
• Web: sana.com
• Phone: 206-701-7914
• Fax: N/A
• Employees: 380
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $14.25
• High Stock Price Target: $16.00
• Low Stock Price Target: $11.00
• Potential Upside/Downside: +373.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.40)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-283,260,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -84.22%
• Return on Assets: -44.97%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.47
• Quick Ratio: 4.47

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.46 per share
• Price / Book: 2.06

Miscellaneous

• Outstanding Shares: 223,270,000
• Free Float: 153,832,000
• Market Cap: $672.04 million
• Optionable: Optionable
• Beta: 1.60